Cilcare Secures €50,000 Grant for 3D Bioprinted Human Model to Advance Hearing Loss Drug Development
核心洞察
Cilcare (搜索)'s INEAR3D project received a €50,000 grant from the University of Montpellier to develop 3D bioprinted human models for auditory drug screening.
The project aims to reconstruct the round window membrane using stereolithography DLP technology to overcome drug delivery barriers in the inner ear.
This human-cell-derived platform will replace animal testing while enabling high-throughput testing of drug diffusion and formulation strategies for hearing loss therapies.
Cilcare (搜索) has announced that its innovative INEAR3D project has been selected by the Companies & Campus initiative, supported by the University of Montpellier and its Pôle Universitaire d'Innovation (PEI), securing a €50,000 grant in recognition of its scientific impact and alignment with health and sustainability priorities. Led by Dr. Sylvie Pucheu, Director of Preclinical Innovation at Cilcare, the project represents a significant advancement in developing human-based in vitro models for auditory drug screening.
Addressing Critical Barriers in Hearing Loss Treatment
Hearing loss stands as the most common sensory disorder in humans and represents a major public health issue worldwide. Despite this prevalence, the effectiveness of auditory treatments remains limited, particularly due to challenges in drug delivery to the inner ear. The round window membrane (RWM) acts as a critical biological barrier between the middle and inner ear, limiting the diffusion and bioavailability of active pharmaceutical compounds.
"The inaccessibility of the cochlea and lack of human cellular models are two major barriers to developing effective treatments for sensorineural hearing loss," explains Dr. Sylvie Pucheu. "With INEAR3D, we aim to overcome these limitations by providing a highly reliable, human-cell-derived platform that more accurately reflects human biology than traditional animal models."
Revolutionary 3D Bioprinting Technology
The INEAR3D project proposes to reconstruct the round window membrane using advanced 3D bioprinting technologies, specifically stereolithography DLP (Digital Light Processing). The printed hydrogel structure will mimic the native membrane's multilayer composition, incorporating specific human cell types and extracellular matrix properties. This in vitro model will enable high-throughput testing of drug diffusion and formulation strategies.
The biomimetic tool is designed to better study and predict how drugs pass through the complex membranes of the inner ear, addressing a fundamental challenge in auditory therapeutics development. The goal extends beyond accelerating drug development to reducing animal testing in line with the 3Rs principle (Replace, Reduce, Refine).
"This model will allow us to test compounds and biotherapies more ethically and more efficiently, ultimately accelerating the discovery of new hearing loss therapies," adds Dr. Pucheu.
Expected Clinical and Regulatory Impact
The INEAR3D project is carried out in collaboration with the Institut Charles Gerhardt de Montpellier (ICGM), combining academic and industry expertise to advance precision tools in hearing research. By integrating Cilcare (搜索)'s preclinical expertise with cutting-edge materials science, INEAR3D is expected to enable quantitative analysis of drug permeability through the RWM and improve early-stage screening of formulations and excipients.
The platform will serve as a predictive tool to complement in vivo models and support regulatory data packages for CTA/IND filings. The project includes the recruitment of a CIFRE PhD student and strengthens Cilcare (搜索)'s contribution to the dynamic biotech innovation ecosystem in Occitanie, exemplifying the company's commitment to scientific excellence and disruptive innovation in auditory research.